Jyong Biotech Ltd. Ordinary Shares (MENS)

About MENS

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bl…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

27

Website

jyongbio.com/

Fundamentals

1-day range

$2.3$2.42

Market cap

$152.06M

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

$-0.08

Dividend yield

—

Beta

0.97

Avg. volume

86.6K

Jyong Biotech Ltd. Ordinary Shares Competitors

Chosen by industry and closest market cap.

• MENS

  Jyong Biotech Ltd. Ordinary Shares

  $2.37

  ▲ 3.04%
  Market cap $152.06MP/E —
  $1.43$67
• CNTN

  Canton Strategic Holdings Inc. Common Stock

  $2.23

  ▼ 5.32%
  Market cap $154.25MP/E —
  $1.75$7.25
• KRRO

  Korro Bio Inc. Common Stock

  $12.94

  ▼ 2.41%
  Market cap $154.90MP/E —
  $5.2$55.89
• AARD

  Aardvark Therapeutics Inc. Common Stock

  $5.71

  ▼ 13.75%
  Market cap $154.94MP/E —
  $3.35$17.94
• KZIA

  Kazia Therapeutics Limited American Depositary Shares

  $13.59

  ▼ 19.59%
  Market cap $141.81MP/E —
  $4.86$17.4
• OKUR

  OnKure Therapeutics Inc. Class A Common Stock

  $3.78

  ▼ 1.31%
  Market cap $162.39MP/E —
  $2.23$5.38
• LFCR

  Lifecore Biomedical Inc. Common Stock

  $4.58

  ▲ 0.88%
  Market cap $164.67MP/E —
  $3.63$8.98

P/E shows — for peers not currently carrying a live signal of their own.